GLP-1 Compounding Pharmacies

GLP-1 Compounding Pharmacies: What's Legal in 2026 and Who's Still Operating

Editorial Independence: Telehealth Ally does not accept payment from pharmacies for placement. FDA enforcement status is tracked using public FDA records. Patient safety comes before engagement — pharmacies with active warning letters are flagged and excluded.

Regulatory Alert — April 2026: FDA enforcement of compounded GLP-1s has accelerated. The agency issued 55+ warning letters in September 2025 and a further 30 on March 3, 2026. The legal landscape is changing week to week. All regulatory status information in this directory reflects public FDA records as of April 2026.

If you've been using a compounded GLP-1 and your pharmacy recently shut down or lost legal authorization, you're not alone. Thousands of patients are in the same position right now. This page explains what's still legal, which pharmacies are still operating under proper oversight, and what to look for when choosing one.

The Short Version

Standard compounded semaglutide became illegal for most pharmacies in April–May 2025, after FDA declared the brand-name shortage resolved in February 2025. The shortage was what gave compounding pharmacies the legal authority to produce GLP-1 copies. Once it ended, that authority evaporated for standard formulations.

What remains potentially legal: clinically differentiated formulations — typically semaglutide or tirzepatide combined with add-in compounds like B12 (cyanocobalamin) or niacinamide, or delivered via oral dissolving tablet (ODT) instead of injection. FDA has not definitively settled the clinical differentiation question, and it remains a legal gray area subject to ongoing enforcement.

The pharmacies that survive long-term are registered 503B outsourcing facilities and PCAB-accredited 503A pharmacies producing only these differentiated formulations — with documented clinical rationale for each.

What Is a Compounding Pharmacy?

Compounding pharmacies create customized medications not commercially available in standard form. There are two distinct types operating in the GLP-1 space.

503A pharmacies are state-licensed and regulated by state pharmacy boards. They compound medications for individual patient prescriptions — meaning each preparation is for a specific named patient with a valid prescription. They are not FDA-registered and are not permitted to bulk-produce medications for general distribution.

503B outsourcing facilities are FDA-registered and subject to FDA's current Good Manufacturing Practice (cGMP) standards. They can legally produce medications in batch quantities for distribution to healthcare facilities and licensed providers. Their quality oversight is substantially more rigorous than 503A pharmacies.

Why compounded GLP-1s grew: When Novo Nordisk and Eli Lilly couldn't meet demand for Ozempic, Wegovy, and Mounjaro between 2022 and 2024, FDA added these drugs to its official shortage list. Under federal law, that shortage designation gave compounding pharmacies legal authority to prepare these drugs without brand-name restrictions. Demand exploded.

Why they're being shut down: FDA removed semaglutide from the shortage list in February 2025 and tirzepatide in the same period. Without an active shortage, standard compounding of these drugs became illegal for most pharmacies. The FDA moved quickly: 55+ warning letters in September 2025, 30 more on March 3, 2026.

The "clinically differentiated" argument: Some pharmacies argue their formulations are not copies of brand-name drugs because they include additional compounds (B12, niacinamide) or use alternative delivery routes (ODTs, sublingual). FDA has disputed many of these claims but has not uniformly rejected them. This remains a genuine legal gray area. Patients using these formulations should understand they are operating in regulatory uncertainty.

How We Evaluate Compounding Pharmacies

We assess compounding pharmacies on six criteria:

1. Accreditation. PCAB (Pharmacy Compounding Accreditation Board) is the gold standard for compounding quality. ACHC (Accreditation Commission for Health Care) is also recognized. State board in good standing is a baseline requirement.

2. Registration type. 503B outsourcing facilities operate under FDA cGMP oversight — a higher quality standard than 503A. 503A pharmacies vary widely in quality.

3. FDA enforcement status. We check FDA's public warning letter database. Any pharmacy with an unresolved warning letter related to GLP-1 compounding is excluded from this directory.

4. Transparency. Does the pharmacy publish pricing (even prescriber-facing)? Are ingredients and add-in compounds listed? Is third-party Certificate of Analysis (COA) testing available?

5. Telehealth integration. Which providers use this pharmacy as their dispensing backend? Reputable telehealth platforms do their own pharmacy vetting.

6. Patient feedback. Google rating and review volume, screened for recency and specificity.

GLP-1 Compounding Pharmacies Directory

The following pharmacies are operating legally in the compounded GLP-1 space as of April 2026, based on publicly available accreditation and FDA enforcement records. Pricing for compounded GLP-1s is typically only available through a prescribing telehealth provider — most pharmacies do not publish patient-facing retail prices.

Excluded pharmacies: Kin Meds, GoodGirlRx, WeightCare, and PharmaZee are not included. All four received FDA warning letters for illegal GLP-1 compounding and should not be used for GLP-1 medications.

Notes on Each Pharmacy

Empower Pharmacy is the largest established compounder in the GLP-1 space. It operates as both a 503B outsourcing facility and a 503A pharmacy — the 503B side means batch production under FDA cGMP oversight, the highest quality standard in compounding. Empower is PCAB-accredited and has no known FDA warning letters as of April 2026. Many telehealth platforms use Empower as their dispensing backend, meaning patients enrolled in programs like some Ro or Hims-era compounded protocols were often receiving Empower-produced medications. Empower recently cut prices up to 70% on some formulations. Pricing is typically provider-negotiated.

Belmar Pharmacy, founded in 1985, is one of the oldest PCAB-accredited compounders in the country. Based in Englewood, Colorado, it serves all 50+ states. The 3.7 Google rating (190 reviews) is below average for pharmacies generally — read recent reviews carefully before relying on this as your primary pharmacy.

Curexa (founded 2003) is PCAB-accredited and serves all 50+ states. At 43 Google reviews, the sample size is small enough that a few negative experiences can skew the rating significantly. Independently verify current availability before starting treatment.

Beaker Pharmacy has the strongest patient review profile in this directory at 4.2 stars across 165 reviews — meaningful volume for a compounding pharmacy. PCAB accreditation status was not confirmed at time of writing; verify directly before use.

Casa Pharma RX has the highest Google rating here (4.5 stars), but only 14 reviews. That sample is too small to draw reliable conclusions. Treat this as an early signal rather than an established quality record.

Hallandale Pharmacy in Hallandale Beach, Florida, operates a tiered pricing model for prescribers. Specific accreditation and state availability data were not confirmed at time of writing; verify directly.

How to Verify a Compounding Pharmacy Before You Use It

The pharmacy market is moving fast, and directory information ages quickly. Before using any compounding pharmacy for GLP-1 medications, verify the following yourself:

Step 1 — Check FDA's 503B outsourcing facility list. FDA maintains a public database of registered 503B facilities at fda.gov. If a pharmacy claims 503B status, verify it there before anything else.

Step 2 — Search FDA's warning letter database. FDA posts warning letters publicly. Search the pharmacy name. A warning letter for GLP-1 compounding means FDA has found illegal activity — do not use that pharmacy for GLP-1 medications regardless of what the pharmacy claims about the letter's status.

Step 3 — Verify PCAB accreditation. PCAB maintains a public directory of accredited pharmacies at pcab.pharmacy. If a pharmacy claims PCAB accreditation, it should appear here.

Step 4 — Check your state's pharmacy board. Each state board maintains a license lookup tool. The pharmacy should be licensed in the state where you receive your prescription.

Step 5 — Ask for documentation. Before your first order, ask for the Certificate of Analysis (COA) from third-party testing for the specific batch you're receiving. Ask whether the pharmacy follows USP <797> standards for sterile compounding. Ask about storage and cold-chain protocols.

Red flags to avoid:

• No verifiable physical address
• Sells GLP-1 medications directly without a valid prescription
• Claims the compounded drug is "the same as" Ozempic or Mounjaro
• Cannot provide a third-party COA on request
• Offers substantial discounts with no clinical rationale for why they're cheaper than other verified pharmacies

What To Do If Your Compounding Pharmacy Shut Down

If your pharmacy received an FDA warning letter and stopped shipping, your options are:

Switch to a branded alternative. Novo Nordisk's NovoCare program and Eli Lilly's LillyDirect offer brand-name Ozempic, Wegovy, Mounjaro, and Zepbound with manufacturer savings programs. Monthly costs vary significantly by insurance status, but list prices have come down substantially since 2024. See our guide to novocare pharmacy direct pricing for current details.

Switch telehealth providers. Many telehealth platforms have transitioned fully to branded medications via manufacturer partnerships. Some GLP-1 telehealth providers now offer brand-only programs at competitive prices. Compare before switching.

Find a PCAB-accredited 503B pharmacy via your current prescriber. If you want to stay on compounded medications, your prescriber may have existing relationships with verified pharmacies. Ask specifically whether they work with PCAB-accredited 503B facilities.

The compounding market is contracting and won't stabilize while enforcement accelerates. Telehealth platforms built on compounded GLP-1s as their core product are facing serious business model risk. For most patients, branded medications via telehealth or direct manufacturer programs are the more durable choice. We cover the options in our GLP-1 compounding alternatives guide.

Frequently Asked Questions

Is compounded semaglutide still legal in 2026?

Standard compounded semaglutide — meaning a copy of the brand-name formulation — is not legal for most purposes since FDA removed semaglutide from the shortage list in February 2025. Clinically differentiated formulations (semaglutide with B12, semaglutide ODTs) remain in a legal gray area. FDA has challenged many of these as non-differentiated copies; enforcement has accelerated since September 2025. If you are using compounded semaglutide, verify that your pharmacy's specific formulation has documented clinical differentiation rationale and no active FDA warning letters.

What's the difference between 503A and 503B compounders?

503A pharmacies are state-licensed and produce medications for individual patient prescriptions. Quality and oversight vary significantly between states. 503B outsourcing facilities are FDA-registered, must follow FDA cGMP standards, and are subject to FDA inspection. For GLP-1 compounding specifically, 503B facilities carry higher regulatory oversight and are a lower-risk choice.

Why is pricing unavailable?

Most compounding pharmacies do not publish patient-facing prices because their business model is B2B — they supply to telehealth providers who set the final patient price. If you're trying to compare costs, the relevant comparison is between telehealth platforms, not pharmacies directly. See our GLP-1 provider comparison for current platform pricing.

How do I know if my current pharmacy is still legal?

Search FDA's warning letter database for your pharmacy's name. Check FDA's 503B outsourcing facility registry if they claim that status. Verify PCAB accreditation at pcab.pharmacy. If your pharmacy is not in FDA's 503B registry, not PCAB-accredited, and not on your state pharmacy board's active license list in good standing, treat that as a serious red flag.

What about tirzepatide compounding?

The same rules apply. FDA added tirzepatide to the shortage list during the Mounjaro/Zepbound supply crunch and removed it as supplies normalized. Standard compounded tirzepatide faces the same legal pressures as semaglutide. Clinically differentiated formulations (tirzepatide with niacinamide) follow the same uncertain legal gray area. The same verification steps apply.

The Bottom Line

The compounding pharmacy market for GLP-1s is contracting fast and will continue to do so. The FDA has been clear about direction: enforcement is accelerating, and the agency has not backed down on the position that shortage-driven compounding authority expired when the shortage did.

For most patients, the practical recommendation is to plan a transition to branded medications. The price gap between compounded and branded has narrowed substantially since 2024, and branded medications carry no regulatory risk of supply disruption from enforcement actions.

If you continue using compounded GLP-1s, use only PCAB-accredited 503B facilities with no active FDA warning letters. Verify everything in this directory yourself using the steps above — directory information ages faster than we can update it in this market.

Current telehealth provider comparisons are in our provider directory. The compounding crackdown timeline is covered in our GLP-1 compounding crackdown guide, and alternatives to compounded medications are in the compounding alternatives guide.